Objective:To examine the effectiveness of postoperative chemotherapy for para-aortic lymph node (PAN) metastasis in patients with endometrial cancer. Methods:Among 350 clinical stage I-II endometrial cancer patients who underwent systemic pelvic and para-aortic lymphadenectomy during the period 1995 through 2002,26 patients were identified with PAN metastasis. Of these patients,nine had only one positive PAN and 17 had two or more positive PANs (mean 4.9,range 1-22). All patients were treated postoperatively with a single chemotherapy regimen consisting of ifosfamide,epiadriamycin,and cisplatin scheduled for 5 cycles. Median (range) follow-up for surviving patients was 85 (38-119) months. Treatment outcome,including disease-free survival relative to the number of positive PANs,was investigated. Results:Among the 26 patients with PAN involvement,four developed recurrence. Three of the four patients had 10 or more positive PANs. Estimated 5-year disease-free survival rates were 89%for patients with one positive PAN,82%for those with two or more positive PANs,and 85%for all patients. No significant difference was identified between the first two groups (P = 0.6543). Conclusions:Postoperative chemotherapy can yield a favorable outcome in endometrial cancer patients with PAN metastasis,even those with multiple positive nodes. Objective: To examine the effectiveness of postoperative chemotherapy for para-aortic lymph node (PAN) metastasis in patients with endometrial cancer. Methods: Among 350 clinical stage I-II endometrial cancer patients who underwent systemic pelvic and para-aortic lymphadenectomy during the period 1995 Of these patients, nine had only one positive PAN and 17 had two or more positive PANs (mean 4.9, range 1-22). All patients were treated postoperatively with a single chemotherapy regimen of ifosfamide, epiadriamycin, and cisplatin scheduled for 5 cycles. Median (range) follow-up for surviving patients was 85 (38-119) months. Treatment outcome, including disease-free survival relative to the number of positive PANs, was investigated. Three of the four patients had 10 or more positive PANs. Estimated 5-year disease-free survival rates were 89% for pa tients with one positive PAN, 82% for those with two or more positive PANs, and 85% for all patients. No significant difference was identified between the first two groups (P = 0.6543). Conclusions: Postoperative chemotherapy can yield a favorable outcome in endometrial cancer patients with PAN metastasis, even those with multiple positive nodes.